SG11201910053YA - Trisubstituted pyrimidine compounds and compositions for the treatment of cancer, retinal disorders, and cardiomyopathies - Google Patents

Trisubstituted pyrimidine compounds and compositions for the treatment of cancer, retinal disorders, and cardiomyopathies

Info

Publication number
SG11201910053YA
SG11201910053YA SG11201910053YA SG11201910053YA SG 11201910053Y A SG11201910053Y A SG 11201910053YA SG 11201910053Y A SG11201910053Y A SG 11201910053YA SG 11201910053Y A SG11201910053Y A SG 11201910053YA
Authority
SG
Singapore
Prior art keywords
international
treatment
california
pct
compounds
Prior art date
Application number
Inventor
Vivo Marco De
Anand Ganesan
Martínez Jose Antonio Ortega
Sohail Jahid
Original Assignee
Fondazione St Italiano Tecnologia
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fondazione St Italiano Tecnologia, Univ California filed Critical Fondazione St Italiano Tecnologia
Publication of SG11201910053YA publication Critical patent/SG11201910053YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

WO 18/ 203 25 6 Al N (I) (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 08 November 2018 (08.11.2018) WIPO I PCT omit °nolo oimIE (10) International Publication Number WO 2018/203256 Al (51) International Patent Classification: CO7D 401/04 (2006.01) A61K 31/506 (2006.01) CO7D 401/14 (2006.01) A61P 35/00 (2006.01) C07D 405/04 (2006.01) (21) International Application Number: PCT/IB2018/053047 (22) International Filing Date: 02 May 2018 (02.05.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 102017000047189 02 May 2017 (02.05.2017) IT (71) Applicants: FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA [IT/IT]; Via Morego, 30, 16163 Geno- va (IT). THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 12th Floor, 1111 Franklin Street, Oakland, California 94607-5200 (US). (72) Inventors: DE VIVO, Marco; Via Orlando 14/17, 16146 Genova (IT). GANESAN, Anand; 202 Sprague Hall, Irvine, California 92697-2400 (US). ORTEGA MARTINEZ, Jose Antonio; Via Pollen 3/2L, 16125 Gen- ova (IT). JAHID, Sohail; 250 Sprague Hall, Irvine, Cali- fornia 92697-2400 (US). (74) Agent: CASCIANO, Lidia et al.; Studio Torta S.p.A., Via Viotti, 9, 10121 Torino (IT). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE (54) Title: TRISUBSTITUTED PYRIMIDINE COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, RETINAL DISORDERS, AND CARDIOMYOPATHIES (57) : The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof: It further discloses a phar- maceutical composition comprising the compounds of Formula (I) and their us- es, in particular in the treatment of diseases or disorders associated to increased relative to physiological or desired RhoJ/Cdc42 levels of expression or function.
SG11201910053Y 2017-05-02 2018-05-02 Trisubstituted pyrimidine compounds and compositions for the treatment of cancer, retinal disorders, and cardiomyopathies SG11201910053YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102017000047189A IT201700047189A1 (en) 2017-05-02 2017-05-02 COMPOUNDS AND COMPOSITIONS FOR CANCER TREATMENT, RETINAL DISORDERS AND CARDIOMYOPATHIES
PCT/IB2018/053047 WO2018203256A1 (en) 2017-05-02 2018-05-02 Trisubstituted pyrimidine compounds and compositions for the treatment of cancer, retinal disorders, and cardiomyopathies

Publications (1)

Publication Number Publication Date
SG11201910053YA true SG11201910053YA (en) 2019-11-28

Family

ID=59746302

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201910053Y SG11201910053YA (en) 2017-05-02 2018-05-02 Trisubstituted pyrimidine compounds and compositions for the treatment of cancer, retinal disorders, and cardiomyopathies

Country Status (9)

Country Link
US (2) US11198682B2 (en)
EP (2) EP3619202B1 (en)
JP (1) JP2020518595A (en)
KR (1) KR102632109B1 (en)
CN (2) CN112279833B (en)
CA (1) CA3062260A1 (en)
IT (1) IT201700047189A1 (en)
SG (1) SG11201910053YA (en)
WO (1) WO2018203256A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11952366B2 (en) 2017-05-02 2024-04-09 Fondazione Istituto Italiano Di Tecnologia Substituted 1,3,5-triazines as inhibitors for a rho family of GTP-ases

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3122354A1 (en) * 2018-12-17 2020-06-25 Tolremo Therapeutics Ag Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer
JP7395723B2 (en) * 2019-10-02 2023-12-11 トルレモ・セラピューティクス・アクチェンゲゼルシャフト Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer
WO2021159993A1 (en) * 2020-02-14 2021-08-19 Pharmablock Sciences (Nanjing) , Inc. Inhibitors of interleukin-1 receptor associated kinase (irak) /fms-like receptor tyrosine kinase (flt3), pharmaceutical products thereof, and methods thereof
CN117355512A (en) * 2021-04-07 2024-01-05 托雷莫治疗股份公司 Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001292670A1 (en) * 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
AU2003295776B2 (en) * 2002-11-21 2011-05-12 Novartis Vaccines And Diagnostics, Inc. 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer
GB0305929D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
GEP20125589B (en) * 2008-05-23 2012-07-25 Wyeth Llc TRIAZINE COMPOUNDS AS P13 KINASE AND mTOR INHIBITORS
US20130023497A1 (en) * 2009-06-08 2013-01-24 Chunlin Tao Triazine Derivatives and their Therapeutical Applications
WO2012101654A2 (en) * 2011-01-25 2012-08-02 Sphaera Pharma Pvt. Ltd Novel triazine compounds
US9815820B2 (en) * 2012-10-05 2017-11-14 Kadmon Corporation, Llc Rho kinase inhibitors
CN105164114B (en) * 2013-05-01 2018-03-23 豪夫迈·罗氏有限公司 The miazines and their purposes of the Heterocyclylalkyl substitution of C connections
IT201700047189A1 (en) 2017-05-02 2018-11-02 Fondazione St Italiano Tecnologia COMPOUNDS AND COMPOSITIONS FOR CANCER TREATMENT, RETINAL DISORDERS AND CARDIOMYOPATHIES

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11952366B2 (en) 2017-05-02 2024-04-09 Fondazione Istituto Italiano Di Tecnologia Substituted 1,3,5-triazines as inhibitors for a rho family of GTP-ases

Also Published As

Publication number Publication date
EP3825310A1 (en) 2021-05-26
CN110799505B (en) 2022-08-30
CA3062260A1 (en) 2018-11-08
CN112279833A (en) 2021-01-29
EP3619202B1 (en) 2021-06-30
KR20200015515A (en) 2020-02-12
US11198682B2 (en) 2021-12-14
KR102632109B1 (en) 2024-01-31
CN112279833B (en) 2024-04-16
EP3619202A1 (en) 2020-03-11
CN110799505A (en) 2020-02-14
IT201700047189A1 (en) 2018-11-02
US20220242848A1 (en) 2022-08-04
WO2018203256A1 (en) 2018-11-08
US20200062733A1 (en) 2020-02-27
JP2020518595A (en) 2020-06-25
US11952366B2 (en) 2024-04-09

Similar Documents

Publication Publication Date Title
SG11201910053YA (en) Trisubstituted pyrimidine compounds and compositions for the treatment of cancer, retinal disorders, and cardiomyopathies
SG11201809342YA (en) Pyrimidine compounds as jak kinase inhibitors
SG11201810117WA (en) Human platelet lysate derived extracellular vesicles for use in medicine
SG11201809301YA (en) Isoquinolin-3-yl carboxamides and preparation and use thereof
SG11201804373VA (en) Compositions and methods for immunooncology
SG11201808566WA (en) Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11202000266VA (en) Quinoline derivatives for treating infections with helminths
SG11201907435PA (en) Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
SG11201807913XA (en) Stabilized soluble pre-fusion rsv f proteins
SG11201809751XA (en) Egfr inhibitor compounds
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201903326RA (en) Liposomal formulation for use in the treatment of cancer
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201808686VA (en) Synthesis of indazoles
SG11201901850XA (en) Dopamine-b-hydroxylase inhibitors
SG11201901249YA (en) Aza-indazole compounds for use in tendon and/or ligament injuries
SG11201908691PA (en) Compounds and methods for the treatment of parasitic diseases
SG11201810318RA (en) Compounds for promoting hair growth and/or inhibiting or delaying hair loss in humans, and compositions for such uses
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201804587QA (en) Isoindole compounds
SG11201809237RA (en) Oxaborole esters and uses thereof